Search results
Results from the WOW.Com Content Network
Microscopic colitis refers to two related medical conditions which cause diarrhea: collagenous colitis and lymphocytic colitis. [ 2 ] [ 3 ] Both conditions are characterized by the presence of chronic non-bloody watery diarrhea , normal appearances on colonoscopy and characteristic histopathology findings of inflammatory cells.
Collagenous colitis is an inflammatory condition of the colon.Together with the related condition lymphocytic colitis, it is a subtype of microscopic colitis, which is characterized by inflammation that specifically affects the colon (i.e. colitis), and a clinical presentation that involves watery diarrhea but a lack of rectal bleeding.
What causes microscopic colitis and who gets it? It occurs in males and females of all ages, but women are more likely to be affected and it mostly presents later in adulthood.
Over-the-counter antidiarrheal drugs may be effective for some people with lymphocytic colitis. Anti-inflammatory drugs, such as salicylates, mesalazine, and systemic corticosteroids may be prescribed for people who do not respond to other drug treatment. The long-term prognosis for this disease is good with a proportion of people suffering ...
The signs and symptoms of colitis are quite variable and dependent on the cause of the given colitis and factors that modify its course and severity. [2]Common symptoms of colitis may include: mild to severe abdominal pains and tenderness (depending on the stage of the disease), persistent hemorrhagic diarrhea with pus either present or absent in the stools, fecal incontinence, flatulence ...
These results build on the growing body of evidence for mirikizumab, which is approved in the U.S. for the treatment of moderately to severely active ulcerative colitis in adults [and] under ...
Less common causes of this symptom profile are carcinoid syndrome, microscopic colitis, bacterial overgrowth, and eosinophilic gastroenteritis; IBS is, however, a common presentation, and testing for these conditions would yield low numbers of positive results, so it is considered difficult to justify the expense. [75]
Bristol Myers Squibb (BMY) has announced positive results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients ...